Plain-English translation of NCT07246421 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand why some people with type 2 diabetes develop a fatty liver and whether their bodies respond differently to a hormone called glucagon. This study will compare how the body handles glucagon in people with type 2 diabetes who do and don't have fatty liver disease, using blood tests, imaging scans, and tissue samples.
Fatty liver disease is common in people with type 2 diabetes and increases the risk of heart problems, but doctors don't fully understand why some people develop it while others don't. This research aims to uncover whether a breakdown in how the body responds to glucagon is part of the problem.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic three times over several weeks. During these visits, you'll have body composition scans, liver imaging, blood tests, a small fatty tissue sample taken from your abdomen, and an 8-hour test where researchers measure how your body responds to glucagon infusions. You may also have a PET-CT scan to look at your metabolism in detail.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Denmark
Sponsor
University of Aarhus
Collaborators
Novo Nordisk A/S
Enrollment target
~24 participants
Started
January 2026
Primary completion
July 2027
Age range
30 Years – 70 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kia E. Fonfara, Medical Doctor
University of Aarhus
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.